Press Releases |News

02/23/2023

Tempus Announces New Multi-omics Collaboration with Actuate Therapeutics

Tempus, a leader in artificial intelligence and precision medicine, today announced a brand-new multi-omics collaboration with Actuate Therapeutics, Inc. (Actuate), a clinical-stage biopharmaceutical company, to support its ongoing Phase 1/2 Study of elraglusib, formerly known as 9-ING-41 (NCT03678883). The Tempus’ xF+ liquid biopsy and Research Use Only (RUO) DNA methylation tests wi...

01/05/2023

Tempus Announces Prospective Study for Biomarker Discovery in Small Cell Lung Cancer

Tempus, a leader in artificial intelligence and precision medicine, today announced a prospective study (NCT05257551), in collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN), that aims to identify biomarkers of response in patients with small cell lung cancer (SCLC). The study, titled Sculptor, is co-sponsored by Tempus and AstraZeneca’s Personalize SCLC Initiative and is cur...

06/06/2022

Tempus Announces 14 Abstracts Accepted For Presentation at the American Society of Clinical Oncology Annual Meeting 2022

Tempus, a leader in artificial intelligence and precision medicine, today announced abstracts accepted for presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, which convenes in Chicago from June 3-7, 2022. Tempus is presenting fourteen abstracts, including one oral presentation, two poster discussions, and eleven poster presentations. “The re...

02/08/2022

Clinical Trials

Tempus Announces the Acquisition of Highline Sciences

Tempus, a leader in artificial intelligence and precision medicine, today announced the acquisition of Highline Sciences, a specialized, full-service clinical contract research organization (CRO) focused on oncology. Highline Sciences manages and executes on early and late-stage clinical trials, applying a customized approach to each study. Highline’s capabilities and expertise will he...

01/13/2022

Tempus Announces Open Enrollment for Study in Collaboration with GSK to Evaluate Niraparib in Advanced Solid Tumor Patients with PALB2 Mutations

Tempus, a leader in artificial intelligence and precision medicine, today announced the commencement of an open label phase II study, in collaboration with GlaxoSmithKline (GSK) to evaluate the efficacy and safety of ZEJULA (niraparib), a poly (ADP-ribose) polymerase (PARP) inhibitor used for patients with advanced or metastatic solid tumors and a germline...

12/01/2021

Tempus Announces Agreement with Janssen R&D to Leverage AI/ML and Real-World Evidence to Enhance the Discovery and Development of Oncology Therapies

Tempus, a leader in artificial intelligence and precision medicine, today announced the expansion of its multi-year agreement with Janssen Research & Development, LLC (Janssen). The expanded scope is anchored in new AI-based work, in which Tempus will collaborate with a multidisciplinary team of data scientists at Janssen to enhance the discov...

11/16/2021

Tempus Incorporates OncoKB Data and NCCN Guidelines Into Its Clinical Reports

Tempus is integrating information from the Memorial Sloan Kettering Cancer Center’s OncoKB database and NCCN Guidelines into its clinical reports, providing physicians robust, well-vetted guidelines at their fingertips Tempus, a leader in artificial intelligence and precision medicine, today announced that it will incorporate data from both the Memor...

11/08/2021

Kronos Bio and Tempus Announce Multi-Year Collaboration to Provide Kronos Bio With Access to Tempus’ Platform

Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, and Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year collaboration that provides Kronos Bio with access to Tempus’ real-world genomic and transcriptomic data and data analytics...

09/09/2021

Clinical Trials

‘Molecular Twin’ Initiative Will Help Advance Precision Cancer Treatment

Cedars-Sinai Cancer and Tempus, a leader in artificial intelligence and precision medicine, are harnessing the power of big data and AI to design personalized cancer treatment options by creating virtual replicas of patients’ DNA, RNA, protein and other information to help identify the most effective approach to each...

08/17/2021

Clinical Trials

Tempus Submits PMA Application to the FDA for its xT-Onco Assay

Tempus, a leader in artificial intelligence and precision medicine, today announced the submission of a Premarket Approval (PMA) application for its proprietary broad-panel DNA sequencing assay to the U.S. Food and Drug Administration (FDA). Tempus is seeking approval for its xT-Onco assay, a broad-panel next-generation sequencing-based, in vitro di...

NEWS

Press Releases

Media Coverage

Additional Partnerships